This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aljada, I. S.
Right arrow Articles by Amsterdam, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aljada, I. S.
Right arrow Articles by Amsterdam, D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 1999, p. 2106-2108, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Mycobacterium bovis BCG Causing Vertebral Osteomyelitis (Pott's Disease) Following Intravesical BCG Therapy

Ibrahim S. Aljada,1 John K. Crane,2 Nancy Corriere,3 Datta G. Wagle,4 and Daniel Amsterdam1,2,3,5,*

Erie County Medical Center3 and Departments of Medicine,2 Microbiology,5 Pathology,1 and Urology,4 School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14215

Received 21 September 1998/Returned for modification 10 November 1998/Accepted 18 March 1999

We report a case of Mycobacterium bovis BCG vertebral osteomyelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer. The recovered isolate resembled M. tuberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect. High-pressure liquid chromatographic studies confirmed the diagnosis of M. bovis BCG infection. The patient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambutol, and PZA. When susceptibility studies were reported, the regimen was changed to isoniazid and rifampin for 12 months. Subsequently, the patient was transferred to a skilled nursing facility for 3 months, where he underwent intensive physical therapy. Although extravesical adverse reactions are rare, clinicians and clinical microbiologists need to be aware of the possibility of disseminated infection by M. bovis BCG in the appropriate setting of clinical history, physical examination, and laboratory investigation.

* Corresponding author. Mailing address: Department of Laboratory Medicine, Erie County Medical Center, 462 Grider St., Buffalo, NY 14125. Phone: (716) 898-3114. Fax: (716) 898-3090. E-mail: AMSTERDAM{at}LAB.ECMC.EDU.

Journal of Clinical Microbiology, June 1999, p. 2106-2108, Vol. 37, No. 6
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Nikaido, T., Ishibashi, K., Otani, K., Yabuki, S., Konno, S., Mori, S., Ohashi, K., Ishida, T., Nakano, M., Yamaguchi, O., Suzutani, T., Kikuchi, S. (2007). Mycobacterium bovis BCG Vertebral Osteomyelitis after Intravesical BCG Therapy, Diagnosed by PCR-Based Genomic Deletion Analysis. J. Clin. Microbiol. 45: 4085-4087 [Abstract] [Full Text]  
  • Mohamed, A. M., Bastola, D. R., Morlock, G. P., Cooksey, R. C., Hinrichs, S. H. (2004). Temperature-Mediated Heteroduplex Analysis for Detection of pncA Mutations Associated with Pyrazinamide Resistance and Differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by Denaturing High- Performance Liquid Chromatography. J. Clin. Microbiol. 42: 1016-1023 [Abstract] [Full Text]  
  • Abu-Nader, R., Terrell, C. L. (2002). Mycobacterium bovis Vertebral Osteomyelitis as a Complication of Intravesical BCG Use. Mayo Clin Proc. 77: 393-397 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»